

Devyser Diagnostics Q3 - High sales growth ahead of additional growth drivers

Redeye embraces the strong sales growth in the quarter, and we emphasise the coming revenue growth drivers that should become more visible during 2024e. Coupled with a strong balance sheet (cash of SEK288m) and 50-60% discount to its peers' EV/sales multiples, we argue the case remains undiscovered by the market, but that next year should likely begin triggering more interest.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Devyser Diagnostics Q3 - High sales growth ahead of additional growth drivers](#)